Amir Kesten

Amir Kesten is currently the Executive Director and Head of Digital Product for Individualized Neoantigen Therapy at Moderna, a position he has held since October 2023. His role focuses on leveraging digital solutions to enhance personalized cancer therapies through neoantigens, which are specific to individual tumors.

Professional Background

• Vice President, Product at Huma (September 2022 - October 2023): Led product initiatives in digital health.
• Vice President, Head of Solutions Consulting / Pre-sales Engineering at BrightInsight (March 2021 - September 2022): Oversaw global pre-sales activities and guided biopharma companies in implementing software as medical devices.
• Senior Director - Head of Digital Health Platform at Teva Pharmaceuticals (July 2016 - September 2019): Managed a medical IoT and data analytics cloud platform.
• Backend Team Lead at Oracle (March 2005 - August 2011): Led a development team for portfolio management products.

Education

• MBA, Executive MBA from Temple University - Fox School of Business and Management.
• MSc and BSc in Computer Science from The Hebrew University of Jerusalem.

Skills and Expertise

Amir possesses a strong background in technology, program management, and commercial strategy, making him a versatile leader in the healthcare technology space. He is fluent in both English and Hebrew.

Recognition

He has received accolades such as the Dean's Certificate of Excellence from Temple University and is a member of the Beta Gamma Sigma international honor society.

For more detailed insights into his professional journey, you can view his LinkedIn profile here .1